olmesartan has been researched along with Fatty Liver in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, YF; Ichijo, H; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T | 1 |
| Enjoji, M; Higuchi, N; Kato, M; Kohjima, M; Kotoh, K; Nakamuta, M; Nakashima, M | 1 |
| Ito, JI; Kawata, S; Ohwada, K; Saito, T; Sasaki, T; Sasaki, Y; Yokozawa, J | 1 |
| Ioshii, SO; Précoma, DB; Sturzeneker, MC; Villela Baroncini, LA | 1 |
| Akisawa, N; Hirose, A; Iwasaki, S; Masuda, K; Nozaki, Y; Oben, JA; Onishi, S; Ono, M; Saibara, T; Takahashi, M; Yoshioka, A | 1 |
| Ando, H; Ishikura, K; Kaneko, S; Kita, Y; Kurita, S; Matsuzawa-Nagata, N; Misu, H; Nabemoto, S; Nakanuma, Y; Ota, T; Takamura, T; Uno, M; Zen, Y | 1 |
1 trial(s) available for olmesartan and Fatty Liver
| Article | Year |
|---|---|
Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Benzimidazoles; Benzoates; Fatty Liver; Female; Hepatitis C, Chronic; Homeostasis; Humans; Hypertension; Imidazoles; Incidence; Insulin Resistance; Japan; Male; Middle Aged; Pilot Projects; Telmisartan; Tetrazoles | 2008 |
5 other study(ies) available for olmesartan and Fatty Liver
| Article | Year |
|---|---|
Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Eating; Endothelium, Vascular; Fatty Liver; Fibrosis; Imidazoles; Insulin Resistance; Male; MAP Kinase Kinase Kinase 5; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; NADPH Oxidases; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Obesity; Reactive Oxygen Species; Signal Transduction; Tetrazoles; Transforming Growth Factor beta1 | 2008 |
Down-regulation of hepatic stearoyl-CoA desaturase 1 expression by angiotensin II receptor blocker in the obese fa/fa Zucker rat: possible role in amelioration of insulin resistance and hepatic steatosis.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Down-Regulation; Fatty Acids, Nonesterified; Fatty Liver; Gene Expression; Imidazoles; Insulin Resistance; Liver; Male; Rats; Rats, Zucker; Stearoyl-CoA Desaturase; Tetrazoles; Triglycerides | 2009 |
Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia.
Topics: Alanine Transaminase; Angiotensin II Type 1 Receptor Blockers; Animals; Aspartate Aminotransferases; Blood Glucose; Cholesterol, Dietary; Disease Models, Animal; Fatty Liver; Hepatitis; Hypercholesterolemia; Imidazoles; Lipids; Liver; Liver Cirrhosis; Male; Non-alcoholic Fatty Liver Disease; Rabbits; Tetrazoles; Time Factors | 2011 |
Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animal Feed; Animals; Choline; Connective Tissue Growth Factor; Fatty Liver; Imidazoles; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Liver Cirrhosis; Male; Methionine; Oxidative Stress; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2007 |
Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Choline Deficiency; Disease Models, Animal; Fatty Acids; Fatty Liver; Imidazoles; Insulin Resistance; Liver Cirrhosis, Experimental; Male; Methionine; Oxidative Stress; Rats; Rats, Long-Evans; RNA, Messenger; Sterol Regulatory Element Binding Protein 1; Tetrazoles; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2008 |